Search

Enter keywords, a title or a report id number below.

Order by Fax Ask a Question Printer Friendly PDF Brochure

Electronic (PDF)

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the title.

EURO€ 384.00USD$ 500.00GBP£ 323.00AUD$ 489.00JPY¥ 49,366.00SEK 3 283,00CHF 471.00CAD$ 509.00
Site License

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access the title.

EURO€ 769.00USD$ 1,000.00GBP£ 647.00AUD$ 978.00JPY¥ 98,733.00SEK 6 566,00CHF 943.00CAD$ 1,019.00
Enterprisewide

Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access the title.

EURO€ 1,153.00USD$ 1,500.00GBP£ 970.00AUD$ 1,467.00JPY¥ 148,099.00SEK 9 849,00CHF 1'414.00CAD$ 1,528.00

Live Chat Live Help Software for Website

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 80

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011', provides an overview of the Leishmaniasis (Kala-Azar) therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala-Azar), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala-Azar). 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leishmaniasis (Kala-Azar).
- A review of the Leishmaniasis (Kala-Azar) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leishmaniasis (Kala-Azar) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Leishmaniasis (Kala-Azar) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Leishmaniasis (Kala-Azar) Overview
Therapeutics Development
An Overview of Pipeline Products for Leishmaniasis (Kala-Azar)
Leishmaniasis (Kala-Azar) Therapeutics under Development by Companies
Leishmaniasis (Kala-Azar) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Leishmaniasis (Kala-Azar) Therapeutics - Products under Development by Companies
Leishmaniasis (Kala-Azar) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Leishmaniasis (Kala-Azar) Therapeutics Development
GlaxoSmithKline plc
MOLOGEN AG
Dafra Pharma International Ltd.
Leishmaniasis (Kala-Azar) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Miltefosine For Leishmaniasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zitromax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ambisome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine + Liposomal Amphotericin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ambisome + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ambisome + Paromomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine + Paromomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amphotericin B Deoxycholate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Amphotericin B + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin Sulfate + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine + Paromomycin Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leish-111f + MPL-SE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AmBisome + Paromomycin Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentostam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin + Gentamicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sitamaquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aluminum Hydroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aluminum Hydroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meglumine Antimoniate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GMCSF + Antimony - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEISH-F2 + MPL-SE Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Amphotericin B + Sodium Stibogluconate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin Sulphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin Sulphate + Sodium Stibogluconate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Interleukin-12 + Aluminum hydroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine + Meglumine Antimoniate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AmBisome + Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paromomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Paromomycin + Glucantime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MGN1331 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glucantime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Azithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Miltefosine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oleylphosphocholine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leishmaniasis (Kala-Azar) Therapeutics – Drug Profile Updates
Leishmaniasis (Kala-Azar) - Featured News
Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
Apr 06, 2010: MOLOGEN AG Receives Funding To Develop A DNA Vaccine Against Hepatitis B
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network

Viewing report

• ORDER BY FAX

• REGISTER

• SELECT SITE CURRENCY

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 80

Customers who bought this item also bought

For enquiries please call us on: